{"url":"https://lda.senate.gov/api/v1/filings/37bb16ef-2caa-4e8b-bba4-8b6e26dd8bd3/","filing_uuid":"37bb16ef-2caa-4e8b-bba4-8b6e26dd8bd3","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2008,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/37bb16ef-2caa-4e8b-bba4-8b6e26dd8bd3/print/","filing_document_content_type":"text/html","income":null,"expenses":"1530000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Jake Hansen, Sr. Vice President, Government Affairs","dt_posted":"2008-10-19T15:23:35-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"25 Massachusetts Avenue, N.W., Suite 440","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":49475,"url":"https://lda.senate.gov/api/v1/registrants/49475/","house_registrant_id":34599,"name":"BARR PHARMACEUTICALS, INC.","description":null,"address_1":"25 Massachusetts Avenue, N.W., Suite 440","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MR. JAKE HANSEN","contact_telephone":"+1 202-728-1010","dt_updated":"2022-04-06T16:07:57.994928-04:00"},"client":{"id":156222,"url":"https://lda.senate.gov/api/v1/clients/156222/","client_id":12,"name":"BARR PHARMACEUTICALS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1999-03-05"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.1038 & S.623, Access to Life-Saving Medicine Act; H.R.1956, Patient Protection & Innvoative Biologic Medicines Act; H.R.5629, Pathway for Biosimilars Act; S.316, Preserve Access to Affordable Generics Act; H.R.1902, Protecting Consumer Access to Generic Drugs Act; Development of \"Pedigree\" or Nat'l Drug Trafficking Sytems; H.R.2900, Food & Drug Administration Amendments Act; H.R.1908 & S.1145, Patent Reform Act; FDA Globalization Act; Tax Incentives/Extensions for R&D Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26824,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"HANSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":42856,"prefix":null,"prefix_display":null,"first_name":"TERRI","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}